NCT06871358View on ClinicalTrials.gov

The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

October 30, 2024

Study Completion Date

November 20, 2024

Conditions
STEMI (STE-ACS)Primary PCI for STEMI
Interventions
DRUG

Atorvastatin 80mg

80 mg of Atorvastatin are loading in first medical contact (Emergency Department) before primary PCI

DRUG

Placebo

Only given a loading DAPT without loading Atorvastatin 80 mg

Trial Locations (1)

57126

RSUD Dr Moewardi, Surakarta

All Listed Sponsors
lead

Universitas Sebelas Maret

OTHER

NCT06871358 - The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients | Biotech Hunter | Biotech Hunter